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ABSTRACT
Objective: The objective of this selective EBM review paper is to determine whether or not,
“Does the use of blinatumomab improve the overall survival rate in adults with
relapsed/refractory acute lymphoblastic leukemia?”
Study Design: A systematic review of two RCTs and one case-based series were utilized. All
studies were published between 2014-2019.
Data Sources: The two RCTs were found through PubMed and the case-based series was
obtained through CINAHL Plus. All the studies were published in peer-reviewed journals.
Outcomes Measured: The main outcome measured in all the studies was overall survival. Both
RCTs defined overall survival as the time from randomization (i.e., when patients are assigned to
receive blinatumomab or standard chemotherapy) to death from any cause. The case-based series
by Topp et. al defined overall survival as the time from the first dose of blinatumomab to death
from any cause.
Results: In the first RCT by Kantarjian et al., the median overall survival was 7.7 months in the
blinatumomab group (95% CI, 5.6 to 9.6) and 4.0 months (95% CI, 2.9 to 5.3) in the
chemotherapy group. The hazard ratio calculated for death was 0.71 (95% CI, 0.55 to 0.93) with
a p-value of 0.01. The second RCT determined median overall survival for the first salvage
group to be 11.1 months for blinatumomab (95% CI, 8.2 months-NR, not reached) and 5.5
months for chemotherapy (95% CI, 3.7–9.0 months), for a hazard ratio of 0.59 (95% CI, 0.38–
0.91); p = 0.016. Median overall survival for second or later salvage was 5.1 months for
blinatumomab (95% CI, 3.2–7.1 months) and 3.0 months for chemotherapy (95% CI, 2.1–4.0
months). A hazard ratio of 0.72 (95% CI, 0.52–1.01) and a p-value of 0.055 was calculated. The
case-based series by Topp et al. revealed shorter overall survival (p=0.201) in patients who
relapsed after previous HSCT (8.8 months) compared with those who relapsed that did not
undergo a prior HSCT (14.1 months).
Conclusions: All three studies in this review indicate that blinatumomab improves overall
survival in patients with relapsed/refractory B cell ALL.
Keywords: Acute lymphoblastic leukemia, Blinatumomab
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a malignant hematological disorder that affects
the B cell or T cell lineage. This review will focus on B-cell ALL, because it is more common,
and because the therapy investigated focuses exclusively on B-cell ALL. In 2021, it is estimated
that 5,960 cases of ALL will be diagnosed.2 Approximately 75 % of these cases are in one of two
age groups: children younger than six and adults over 60.1 Among the adults, incidence of ALL
is 1 to-5 cases per 100,000. The common B-cell lineage type occurs in 67% of ALL cases. 2 The
cause of B-cell ALL is unknown, but ionizing radiation and single polynucleotide
polymorphisms such as GATA3 and CEBPE have been associated with the disease.2
Beyond the cost of human life, the financial costs of ALL are significant. Patients must
be hospitalized for at least 28 days during the induction phase of treatment, and the cost of acute
leukemia treatment is high due to the intensity of the treatment regimen, necessary hospital
admissions, and the possibility of bone marrow transplant.3 One study reported that within the
first year of ALL diagnosis, 93% of patients had at least one ER visit and a prolonged hospital
stay – most commonly for neutropenic fever.4 In total, costs incurred for the first year of ALL
treatment can range up to ~$463,000, and the average out-of-pocket cost is ~$5,100.3
Gold standard treatment for B-cell ALL is divided into four phases of chemotherapy:
induction, intensification, consolidation, and maintenance.1 The purpose of the induction phase is
to induce remission; it typically lasts 4 weeks. In the induction phase, drug combination-based
chemotherapy regimens use cytarabine, cyclophosphamide, vincristine, daunorubicin, and
glucocorticoids.1 Additionally, during the induction phase patients will receive central nervous
system (CNS) prophylaxis, e.g., intrathecal methotrexate, cranial irradiation, or high dose IV
methotrexate.3 During the intensification and consolidation phases, patients receive additional
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chemotherapy to eradicate residual malignant cells. The intensification and consolidation phases
may last for several months.3 The maintenance phase deploys lower dose chemotherapy drugs
for about 2 years to maintain remission.3 Some patients do not respond well to the standard
chemotherapy protocol described above; in this case, they may undergo a hematopoietic stem
cell transplant (HSCT) and receive rituximab for CD20+ ALL.1,3 In practice, more than 80% of
adults with ALL will achieve complete remission via chemotherapy, but most adult patients will
experience a relapse.1 Adults with relapsed/refractory B-cell ALL can get further treatment, but
subsequent remission rates range from 18-44%.1 Additionally, some adults will have primary
resistant disease and experience fatal complications from treatment. For patients with relapsed or
refractory ALL, the median overall survival is 2-6 months.2 The 3-to-5-year survival rates after
relapsed/refractory ALL are estimated be less than 10%.2,3
Clearly, it is important to explore ways to increase survival. Thus, immunotherapeutic
options are currently being evaluated for patients with relapsed/refractory ALL. Blinatumomab is
a leading candidate among immunotherapeutic options. Blinatumomab is a bispecific T-cell
engager immunotherapy that attaches to CD-19 positive B cells and to CD-3 positive cytotoxic T
cells which enable the patient’s endogenous T cells to destroy CD 19 ALL blast cells.1
Blinatumomab is FDA-approved for relapsed/refractory Philadelphia (Ph)- negative B cell
precursor ALL.5 It is administered by continuous IV infusion over the course of 28 days
followed by a 2-week treatment free interval.1,5 Maintenance treatment is given as a continuous
IV infusion every 12 weeks.1,5 This paper evaluates two RCTs and a case-based series that assess
the overall survival rate of patients with relapsed/refractory ALL who were administered
treatment with blinatumomab.
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OBJECTIVE
The objective of this selective EBM review paper is to answer the question, “Does the
use of blinatumomab improve the overall survival rate in adults with relapsed/refractory acute
lymphoblastic leukemia?”
METHODS
The target population for the selected studies is adults with relapsed/refractory precursor Bcell ALL. The intervention analyzed in all studies was blinatumomab. The studies explored its
effect on overall survival rate in this patient population. The two RCTs were found on PubMed
and the case-based series was found on CINAHL Plus. All the articles were published in peerreviewed journals in English. The RCTs measured the overall survival rate of the experimental
group that received blinatumomab, and they compared this experimental group to another patient
group that was administered standard chemotherapy.
The case-based series assessed three different patient cohorts utilizing different dosing
regimens of blinatumomab; this study measured overall survival rates for each group. Key words
used in the article search were acute lymphoblastic leukemia and blinatumomab. Inclusion
criteria for this review permitted use of randomized controlled trials that were published within
the last 10 years and studies that included adults 18 years and older. Studies that focused solely
on pediatric patients and observational studies, were excluded. The statistics listed in the articles
for measuring overall survival rate included p-values and hazard ratios.
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Table 1. Demographics & Characteristics of Included Studies
Study

Type

# Patients

Age
(yrs.)
Patients
>18 years
of age

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Kantarjian
20175

RCT

405

(Ph)-negative Bcell precursor ALL
refractory to
induction therapy
or to salvage with
combination
chemotherapy, first
relapse with
remission lasting
less than 1 year,
second or greater
relapse, or relapse
after allogeneic
HSCT, > 5% blasts
in the bone
marrow, and an
Eastern
Cooperative
Oncology Group
(ECOG) score of 2
or less

Other active cancers,
CNS pathology,
autoimmune disease,
acute or chronic
GVHD of grade 2 or
higher, allogeneic
HSCT within 12 weeks
before randomization,
autologous HSCT
within 6 weeks before
randomization,
chemo/radiation within
2 weeks before
randomization,
immunotherapy use
within 4 weeks before
randomization, or
continued use of
investigational
treatment.

29

Blinatumomab
vs.
chemotherapy

Dombret
20196

RCT

405

Patients
>18 years
of age

Adults (>18 years
old) with Ph– Bcell precursor ALL
that was refractory
to chemotherapy,
in first relapse after
chemotherapy with
a first remission
5% blasts in bone
marrow, and
ECOG score of 2
or less

Other active cancers,
pathology of the CNS,
autoimmune disease,
acute or chronic
GVHD of grade 2 or
higher, allogeneic
HSCT within 12 weeks
before the study,
autologous HSCT
within 6 weeks before
randomization,
chemo/radiation within
2 weeks before prior to
study, use of
immunotherapy within
4 weeks before
randomization, or
continued use of
investigational
treatment.

23

Blinatumomab
vs.
chemotherapy

Topp
20147

Case
Based
Series

36

18-77
years old

5% blasts in bone
marrow with
refractory/relapse
disease after
chemo or after
HSCT, ECOG
score of 2 or less,
and life expectancy
of > 12 weeks

(Ph)+ ALL eligible for
dasatinib or imatinib,
CNS disease, GVHD,
infections, antimurine
antibodies,
immunotherapy within
4 weeks, or chemo
within 2 weeks

0

Blinatumomab
was given and
patients were
split into three
cohorts and
given different
doses.
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OUTCOMES MEASURED
The major outcome measured in all three studies was increased overall survival rate with
the use of blinatumomab. Both RCTs defined overall survival as the time from randomization
(i.e., when patients are assigned to receive blinatumomab or standard chemotherapy) to death
from any cause.5,6 The case-based series by Topp et al. defined overall survival as the time from
the first dose of blinatumomab to death from any cause.7 All studies utilized the Kaplan–Meier
method, compared treatment groups using two-sided stratified log-rank tests.5-7
RESULTS
The first study by Kantarjian et al. enlisted 405 adults in a multinational study that
compared blinatumomab to standard chemotherapy and measured the effect the two treatments
had on overall survival. Adults with Ph (-) B cell precursor ALL and refractory or relapsed
disease were enrolled in this trial. Patients were enrolled from January 2014 to September 2015.5
The data cutoff date was January 4, 2016.5
An interactive voice-response system was utilized to randomly assign eligible patients in
a 2:1 ratio to receive open-label treatment with either blinatumomab or standard chemotherapy.5
Randomization was stratified according to age, prior salvage therapy, and earlier hematopoietic
stem-cell transplantation (HSCT). Patients in each treatment group received two cycles of
induction chemotherapy. Additionally, in each group, patients in morphologic remission (≤5%
bone marrow blasts) received up to three cycles of consolidation therapy, and patients in
continued morphologic remission were administered up to 12 months of maintenance therapy.5
Induction and consolidation treatments with blinatumomab were administered in 6-week
cycles. Patients received blinatumomab for 4 weeks (9 μg per day during week 1 of induction
cycle 1 and 28 μg per day by continuous infusion).5 Patients then underwent a 2-week interval
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free of treatment. Maintenance treatment with blinatumomab was administered as 4-week
continuous infusion every 12 weeks via PICC line or port. All patients in the blinatumomab
group received dexamethasone prior to the start of treatment to prevent infusion reactions.5
Patients in the chemotherapy group received one of the following four regimens: fludarabine,
high-dose cytosine arabinoside, and granulocyte colony-stimulating factor with or without
anthracycline; a high-dose cytosine arabinoside–based regimen; a high-dose methotrexate-based
regimen; or a clofarabine-based regimen.5
Adverse events were reported in 99% of patients in the study.5 In the blinatumomab
group, treatment interruptions were required for 32% of patients.5 Only 6 % of patients in the
chemotherapy group, experienced treatment interruptions.5 Overall survival was greater in the
blinatumomab group than in the chemotherapy group. The median overall survival was 7.7
months in the blinatumomab group (95% CI, 5.6 to 9.6) and 4.0 months (95% CI, 2.9 to 5.3) in
the chemotherapy group.5 As reported in Table 2, the hazard ratio calculated for death was 0.71
(95% CI, 0.55 to 0.93) with a p-value of 0.01, which is statistically significant.5 This result
indicates that there is a large treatment effect.
Table 2. Overall Survival of Patients, Blinatumomab vs. Chemotherapy5
No. of Patients
Months
95% confidence

Hazard ratio

Interval

P-value
0.71 (95% CI,
0.55-0.93)
P=0.01

Blinatumomab

271

7.7

(5.6 to 9.6)

Chemotherapy

134

4.0

(2.9 to 5.3)
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The second study by Dombret et al. conducted a RCT in which patients were randomly
allotted in a 2:1 ratio to receive open-label treatment with either blinatumomab or
chemotherapy.6 Patients were stratified according to age, previous salvage therapy, and prior
HSCT. The data cutoff point was in 2016.6 Blinatumomab was administered in 6-week cycles,
consisting of continuous infusion for 4 weeks (9 μg/day during week 1 of induction cycle 1, and
28 μg/day thereafter).6 Patients then did not receive therapy for 2 weeks. Blinatumomab
maintenance was given in 12-week cycles, with continuous infusion for 4 weeks (28 µg/day)
followed by no treatment for 8 weeks.6 All patients who received blinatumomab were
administered dexamethasone within one hour prior to each infusion to prevent infusion
reactions.6
Patients in the chemotherapy group received one of the following regimens: fludarabine,
high-dose cytosine arabinoside, and granulocyte colony-stimulating factor with or without
anthracycline; a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based
regimen; or a clofarabine-based regimen.6 Patients in both groups experienced adverse effects
including neutropenia, increased liver enzymes, cytokine release syndrome, and neurologic
events.6
This study assessed overall survival in patients who were in the first salvage group which
consisted of 167 individuals (104 blinatumomab, 63 chemotherapy). The second/later salvage
group consisted of 238 patients (167 blinatumomab, 71 chemotherapy). As demonstrated in
table 3, median overall survival for the first salvage group was 11.1 months for blinatumomab
(95% CI, 8.2 months-NR, not reached) and 5.5 months for chemotherapy (95% CI, 3.7–9.0
months), for a hazard ratio of 0.59 (95% CI, 0.38–0.91); p = 0.016.6 The p-value of this data
demonstrates statistical significance and displays a large treatment effect. Median overall
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survival for second or later salvage was 5.1 months for blinatumomab (95% CI, 3.2–7.1 months)
and 3.0 months for chemotherapy (95% CI, 2.1–4.0 months).6 A hazard ratio of 0.72 (95% CI,
0.52–1.01) and a p-value of 0.055 was statistically non-significant for the second/later salvage
group.6
Table 3. Overall Survival of First Salvage Patients, Blinatumomab vs. Chemotherapy6
First Salvage
Group

No. of Patients

Months

95% confidence
Interval

Hazard ratio
P-value

Blinatumomab

167

11.1

(8.2, NR*)

Chemotherapy

63

5.5

(3.7 to 9.0)

0.59 (95% CI,
0.38-0.91)
P=0.016

*NR= Not Reached
Table 4. Overall Survival of Second/Later Salvage Patients, Blinatumomab vs.
Chemotherapy6
Second/Later
Salvage Group

No. of Patients

Months

95% confidence
Interval

Hazard ratio
P-value

Blinatumomab
Chemotherapy

167
71

5.1
3.0

(3.2 to 7.1)
(2.1 to 4.0)

0.72 (95% CI,
0.52-1.01)
P=0.055

Topp et al. 2014 conducted a case-based series which consisted of an open-label,
multicenter, single-arm study. Between October 6, 2010, and June 19, 2012, 36 patients were
enrolled and treated at nine centers in Germany.7 Individuals were treated with blinatumomab in
cycles of 4-week continuous infusion followed by a 2-week treatment-free interval with a dosefinding stage and an extension stage.7 During the first 2 days of each cycle, blinatumomab was
administered in the hospital and then monitored on an outpatient basis.7 IV dexamethasone was
administered prior to blinatumomab infusion.7 Three dose cohorts were examined in the dose
finding stage of the study. Cohort 1 included seven patients, five patients in cohort 2a, and six
patients in cohort 2b. In cohort 1, patients were administered 15µg/m2 throughout the treatment
period.7 Patients in cohort 1, displayed the highest rates of adverse effects. One patient
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developed grade 3 nervous system and psychiatric disorder adverse effects.7 Another patient
developed grade 4 cytokine release syndrome; both patients were replaced.7 Patients in cohort 2a
had the lowest rate of adverse effects.
Therefore, the dose schedule of cohort 2a was chosen for the extension stage. In cohort 2a,
patients received blinatumomab at a dose of 5 µg/m2 per day in the first week and then at a dose
of 15 µg/m2 per day for the remainder of the first cycle and all following treatment cycles.7 In
cohort 2b, patients were treated at a dose of 5 µg/m2 per day for the first week, 15 µg/m2 per day
in the second week, and 30 µg/m2 per day in weeks 3 to 4 of the first cycle and for remaining
treatment cycles.7 The article did not mention the adverse effects experienced by patients in
cohort 2b. The extension stage consisted of additional 18 patients who received cohort 2a’s
treatment regimen. As shown in Table 5, a statistically nonsignificant shorter overall survival
(p=0.201) was observed in patients who relapsed after previous HSCT (8.8 months) compared
with those who relapsed that did not undergo a prior HSCT (14.1 months).7
Table 5. Overall Survival of Patients Comparing Prior HSCT vs. No Prior HSCT7
No. of Patients
Months
95% confidence P-value
Interval
No prior HSCT
Prior HSCT

21
15

14.1
8.8

(8.5 to 21.9)
(1.3 to 14.9)

P=0.201

DISCUSSION

The goal of this systematic review is to determine if blinatumomab improves the overall
survival rate in patients with relapsed/refractory Ph (-) negative B-cell ALL. The first study by
Kantarjian et al. demonstrated that blinatumomab resulted in significantly longer overall survival
compared to standard chemotherapy. The risk of death was 29% lower with blinatumomab
(hazard ratio=0.71, p =0.016), and the median duration of survival was 3.7 months longer
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compared to the chemotherapy group.5 A limitation of Kantarjian et al. is that there is
unspecified data for 2 participants in the study which could have influenced the results.5 It is
unknown if one participant had a prior stem cell transplant in the blinatumomab group.
The second study by Dombret et al. showed that overall survival is greater and
statistically significant in patients who received blinatumomab compared to standard
chemotherapy for first salvage (11.1 months CI 95% 8.2, NR, blinatumomab vs. 5.5 months CI
95% 3.7 to 9.0, chemotherapy, p-value=0.016).6 The second salvage group also demonstrated
increased overall survival (5.1 months vs. 3.0 months, p-value=0.055) which is statistically nonsignificant although, it exhibits a trend that suggests further study with a larger sample size might
be useful.6 A limitation to this study is that the data cutoff point could have been later in the
study which may have increased the overall survival.6 Another limitation to this study is that a
investigators were allowed to choose among four different chemotherapy regimens.
The third study by Topp et al. displayed a statistically nonsignificant shorter overall
survival (p = 0.201) in patients who relapsed after previous HSCT (8.8 months) compared with
those who relapsed that did not undergo a prior HSCT (14.1 months).5 A larger sample size in
both groups can improve statistics and the ability to differentiate responses among subgroups
with specific conditions.5 Additionally, this was a case-based series and there was no control
group to compare results among the three cohorts in the study.
Additional studies are providing evidence that blinatumomab may be effective for
patients with relapsed/refractory (Ph) + B cell ALL.8 Although blinatumomab has a black box
warning for neurotoxicity and cytokine release syndrome, most of the adverse effects are
reversible with treatment.8
CONCLUSION
All three studies in this systematic review indicate that blinatumomab does improve the overall
survival in patients with relapsed/refractory B cell ALL in comparison to chemotherapy.
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For future studies, both RCTs mentioned the possibility of combining different immunotherapy regimens
to create a synergistic effect which could reduce the use of chemotherapy.5,6 Ongoing studies are
comparing different immunotherapies and their effect on overall survival.8 Additionally, it would be
beneficial in future studies to have a more objective chemotherapy regimen as investigators could choose
among four different treatments. Randomized controlled trials could have larger sample sizes by including
patients with relapsed/refractory Ph (+) B cell ALL since it has shown efficacy in other studies.5,6
Immunotherapy is demonstrating to be a promising treatment in the field of oncology. It offers hope for
patients with primary resistant or relapsed disease.
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